Idursulfase-beta CNS Delivery via Intracerebroventricular Injection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Hunter syndrome, particularly those involving enzyme replacement therapy, face challenges in effectively delivering therapeutic agents to the central nervous system due to the blood-brain barrier, leading to inadequate therapeutic effects and adverse events associated with intrathecal drug delivery.
Innovation Solution
Intracerebroventricular administration of Idursulfase-beta (IDS-β) using a stable formulation with polysorbate surfactant and buffering agents, allowing direct delivery to the brain ventricles without substantial adverse effects, thereby overcoming the blood-brain barrier and achieving effective distribution across brain regions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If intravenous enzyme replacement therapy is administered, then the treatment covers systemic distribution, but the therapeutic agent cannot adequately cross the blood-brain barrier to treat CNS symptoms
Solution Approach 1:
The patent uses the cerebrospinal fluid (CSF) as an intermediary medium to deliver the enzyme to the CNS. By administering the enzyme intrathecally into the CSF space, the therapeutic agent bypasses the blood-brain barrier and achieves direct distribution to brain and spinal cord tissues, resolving the contradiction between systemic distribution and CNS penetration
2Reliability
If intrathecal injection is used to deliver enzyme to CNS, then the blood-brain barrier is overcome, but device malfunction and adverse events occur
Solution Approach 1:
The patent eliminates the need for complex infusion pumps and delivery devices by using simple intrathecal injection. The enzyme is delivered directly into the CSF space through a straightforward injection procedure, removing the problematic delivery device that causes malfunction and adverse events while maintaining effective CNS delivery
3Reliability
If the blood-brain barrier is made more permeable to allow enzyme entry, then CNS treatment efficacy improves, but protection of the CNS from harmful substances is compromised
Solution Approach 1:
The patent uses the CSF space as an intermediary compartment that allows enzyme delivery without compromising the BBB. The enzyme is introduced directly into the CSF, which naturally circulates around the brain and spinal cord, allowing widespread CNS distribution while the intact BBB continues to protect the CNS from harmful bloodborne substances
Data Source
Figure 1~3(B)
Figure 4~6
Figure 7~10
AI summary
The present invention provides, among other things, compositions and methods for CNS delivery of Idursulfase-beta, a human recombinant iduronate-2-sulfatase protein, for effective treatment of Hunter Syndrome. The compositions and methods provided by the present invention effectively reduce symptoms not only in brain and spinal cord but also in peripheral tissues including heart, liver, spleen, lung, and kidney.